{"id":"W4387809599","doi":"10.1016/j.annonc.2023.10.090","title":"LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"EMD Serono; Genentech; Ipsen; Astellas Pharma; Eisai; Jounce Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Mylan; Arrowhead Pharmaceuticals; EUSA Pharma; AstraZeneca; Associazione Italiana di Oncologia Medica; European Association of Urology; Pfizer; Incyte; F. Hoffmann-La Roche; PTC Therapeutics; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Amgen; Seagen; Society for Immunotherapy of Cancer","keywords":"Medicine; Everolimus; Clear cell renal cell carcinoma; Renal cell carcinoma; Oncology; Internal medicine; Open label; Phases of clinical research; Randomized controlled trial; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001027937,0.001323745,0.002047827,0.0002844653,0.0003308844,0.00102256,0.0007927612,0.001105468,0.006766549],"category_scores_gemma":[0.0008293489,0.0006301561,0.001639752,0.0002775762,0.0007873087,0.001020334,0.0003873768,0.00317637,0.001156108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007895962,"about_ca_system_score_gemma":0.001090071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001865682,"about_ca_topic_score_gemma":0.005539591,"domain_scores_codex":[0.999669,0.0001614465,0.00001618305,0.0000560911,0.00002424071,0.00007311682],"domain_scores_gemma":[0.9995868,0.00007918617,0.00009572458,0.00002522737,0.00002081305,0.0001923016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9597046,0.007878996,0.001311353,0.0005658324,0.001362947,0.00004124721,0.00005633606,0.0005085037,0.003938636,0.0001775995,0.001824056,0.02262996],"study_design_scores_gemma":[0.9200038,0.07220227,0.004811527,0.00003749779,0.0007711133,0.00004479632,0.00004826314,0.0005081649,0.0004234645,0.0001509303,0.0009796662,0.00001849754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918991,0.002447539,0.0003869091,0.0006664218,0.0002635109,0.001055365,0.00116489,0.0001299378,0.001986228],"genre_scores_gemma":[0.9894105,0.001786928,0.0008906833,0.001224017,0.0001997998,0.001242847,0.001502292,0.00002508673,0.003717835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006766549,"threshold_uncertainty_score":0.02263641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.164115545599524,"score_gpt":0.4251918590171163,"score_spread":0.2610763134175923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}